CA2268922C - Methods of treating or preventing cardiac arrhythmia - Google Patents

Methods of treating or preventing cardiac arrhythmia Download PDF

Info

Publication number
CA2268922C
CA2268922C CA002268922A CA2268922A CA2268922C CA 2268922 C CA2268922 C CA 2268922C CA 002268922 A CA002268922 A CA 002268922A CA 2268922 A CA2268922 A CA 2268922A CA 2268922 C CA2268922 C CA 2268922C
Authority
CA
Canada
Prior art keywords
6alkyl
substituted
substituents
aryl
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002268922A
Other languages
English (en)
French (fr)
Other versions
CA2268922A1 (en
Inventor
Joseph J. Lynch, Jr.
Joseph J. Salata
Richard J. Swanson
Bernard Fermini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of CA2268922A1 publication Critical patent/CA2268922A1/en
Application granted granted Critical
Publication of CA2268922C publication Critical patent/CA2268922C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002268922A 1996-10-31 1997-10-29 Methods of treating or preventing cardiac arrhythmia Expired - Fee Related CA2268922C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2934996P 1996-10-31 1996-10-31
US60/029,349 1996-10-31
PCT/US1997/019648 WO1998018476A1 (en) 1996-10-31 1997-10-29 Methods of treating or preventing cardiac arrhythmia

Publications (2)

Publication Number Publication Date
CA2268922A1 CA2268922A1 (en) 1998-05-07
CA2268922C true CA2268922C (en) 2004-12-28

Family

ID=21848595

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002268922A Expired - Fee Related CA2268922C (en) 1996-10-31 1997-10-29 Methods of treating or preventing cardiac arrhythmia

Country Status (8)

Country Link
US (3) US5935945A (enExample)
EP (1) EP0946183B1 (enExample)
JP (1) JP2001503413A (enExample)
AT (1) ATE361078T1 (enExample)
AU (1) AU727391B2 (enExample)
CA (1) CA2268922C (enExample)
DE (1) DE69737689T2 (enExample)
WO (1) WO1998018476A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935945A (en) * 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
CN1217918C (zh) * 1998-04-01 2005-09-07 卡迪欧梅制药公司 氨基环己基醚化合物和其用途
US7507545B2 (en) 1999-03-31 2009-03-24 Cardiome Pharma Corp. Ion channel modulating activity method
US6531495B1 (en) 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
US7057053B2 (en) * 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7524879B2 (en) * 2000-10-06 2009-04-28 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10061876A1 (de) 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US6783979B2 (en) 2001-06-06 2004-08-31 The Trustees Of Columbia University In The City Of New York Research Foundation Of State University Of New York Vectors encoding HCN channels and MiRP1
WO2002098287A2 (en) * 2001-06-06 2002-12-12 The Trustees Of Columbia University In The City Of New York A high throughput biological heart rate monitor that is molecularly determined
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
DE60305200T2 (de) * 2003-05-02 2007-05-10 Cardiome Pharma Corp. Aminocyclohexylether-verbindungen und deren verwendung
US20090041841A1 (en) * 2003-05-02 2009-02-12 Cardiome Pharma Corp. Controlled release tablet formulations for the prevention of arrhythmias
US7345086B2 (en) 2003-05-02 2008-03-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
WO2005018635A2 (en) * 2003-08-07 2005-03-03 Cardiome Pharma Corp. Ion channel modulating activity i
US7345087B2 (en) * 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
DE102004009931A1 (de) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz
US20070134157A1 (en) * 2004-02-26 2007-06-14 Regan Christopher P Biological assay
CA2561819A1 (en) 2004-04-01 2005-12-01 Cardiome Pharma Corp. Prodrugs of ion channel modulating compounds and uses thereof
WO2005097087A2 (en) * 2004-04-01 2005-10-20 Cardiome Pharma Corp. Merged ion channel modulating compounds and uses thereof
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
JP5583325B2 (ja) * 2004-11-08 2014-09-03 カーディオム ファーマ コーポレイション イオンチャネル調節化合物の投与レジメ
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
NO3175985T3 (enExample) 2011-07-01 2018-04-28
JP2015504923A (ja) 2012-01-27 2015-02-16 ギリアード サイエンシーズ， インコーポレイテッド 後期ナトリウムイオンチャネル遮断剤およびカリウムイオンチャネル遮断剤を使用する併用療法
WO2016059191A1 (en) * 2014-10-16 2016-04-21 Academisch Medisch Centrum Nk3 agonist for use in the treatment of a patient suffering from atrial arrhythmia or fibrillation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412864D0 (en) * 1984-05-19 1984-06-27 Smith Kline French Lab Chemical compounds
GB8722776D0 (en) * 1987-09-28 1987-11-04 Smith Kline French Lab Chemical compounds
NZ234087A (en) * 1989-06-19 1991-08-27 Teikoku Hormone Mfg Co Ltd 2-(3-aryloxy(2-hydroxy-propylamino))-2-methylpropyl- aminophenyl pyridazine derivatives
US5428031A (en) * 1991-12-03 1995-06-27 Merck & Co., Inc. Methods of treating cardiac arrhythmia
HU214320B (hu) * 1991-12-20 1998-03-02 EGIS Gyógyszergyár Rt. Eljárás új 3(2H)-piridazinon-származékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5670504A (en) * 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US5506228A (en) * 1995-02-23 1996-04-09 Merck & Co., Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US5935945A (en) * 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia

Also Published As

Publication number Publication date
EP0946183B1 (en) 2007-05-02
US6214809B1 (en) 2001-04-10
CA2268922A1 (en) 1998-05-07
WO1998018476A1 (en) 1998-05-07
AU727391B2 (en) 2000-12-14
ATE361078T1 (de) 2007-05-15
EP0946183A1 (en) 1999-10-06
US5935945A (en) 1999-08-10
US6214810B1 (en) 2001-04-10
DE69737689T2 (de) 2008-01-31
EP0946183A4 (en) 2001-07-18
JP2001503413A (ja) 2001-03-13
AU5154998A (en) 1998-05-22
DE69737689D1 (de) 2007-06-14

Similar Documents

Publication Publication Date Title
US5935945A (en) Methods of treating or preventing cardiac arrhythmia
US5969017A (en) Methods of treating or preventing cardiac arrhythmia
US5900407A (en) Method of treating dry eye disease with uridine triphosphates and related compounds
Robertson et al. Dihydropyridazinone cardiotonics. The discovery and inotropic activity of 1, 3-dihydro-3, 3-dimethyl-5-(1, 4, 5, 6-tetrahydro-6-oxo-3-pyridazinyl)-2H-indol-2-one
JPWO1991016314A1 (ja) ピリダジノン誘導体
EP0355583A2 (en) Cardiotonics
RU2190601C2 (ru) Замещенные гуанидиды коричной кислоты, способ их получения и фармацевтическая композиция
CA2085796C (en) 3(2h)-pyridazinone derivatives and process for the preparation thereof
AU609406B2 (en) Pharmaceutically useful derivatives of thiazolidine-4-carboxylic acid
Hoehner et al. Alteration of voltage-dependent calcium channels in canine brain during global ischemia and reperfusion
EP1341539B1 (en) Anti-inflammatory agents
KR20040072733A (ko) 칼슘채널 차단제로서의 1,4-디하이드로피리딘 및 피리딘화합물
WO1992005190A1 (en) Deoxyhypusyl hydroxylase inhibitors
PT91741B (pt) Processo para a preparacao de piperidinil-imidazois e de composicao farmaceuticasque os contem
US5541201A (en) Antiarrhythmic piperidin-1-yl-2,2-dialkylpropanone arylsulfonamide derivatives
CA1083151A (en) Naphthalenone phthalazinylhydrazones
JP3080131B2 (ja) ピリダジノン誘導体
US4259490A (en) 2-(Substituted amino)benz[cd]indoles
EP0292981A2 (en) 2-Selenomethyl-1, 4-dihydropyridines, a process for the preparation thereof and pharmaceutical compositions containing them
KR840001671B1 (ko) 4-히드록시페닐 알칸올아민 유도체의 제조방법
EP0517877A1 (en) Novel 3(2h)-pyridazinones, pharmaceutical compositions containing them and process for preparing same
Undrovinas et al. Research Article Repolarization abnormalities in cardiomyocytes of dogs with chronic heart failure: role of sustained inward current
JPS617276A (ja) ジヒドロピリジン抗虚血および降圧剤
HK1003108B (en) Cardiotonics
HK1003108A1 (en) Cardiotonics

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20141029